Track topics on Twitter Track topics that are important to you
Nuvectra (NASDAQ:NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has advised that its review of Company’s pre-market approval (PMA) application for its Virtis Sacral Neuromodulation (SNM) system has been extended beyond the expiration of the FDA’s 180-day review period. As quoted in the press release: … Continued
The post Nuvectra Provides Update on Virtis FDA PMA Submission appeared first on Investing News Network.
Original Article: Nuvectra Provides Update on Virtis FDA PMA SubmissionNEXT ARTICLE
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...